Improving blood sugar control in type 1 diabetes using team care, technology, education and peer support
Official title: Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
Run by Second Xiangya Hospital of Central South University · NCT07097805 · Data updated 2026-11-12
This program will try whether combining a care team, diabetes technologies (like CGMs and pumps), structured education, and peer support helps people with type 1 diabetes manage their blood sugar better.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 3000 (estimated) |
| Sponsor | Second Xiangya Hospital of Central South University Academic / other |
| Locations | 10 sites (Beijing, Beijing Municipality and 9 other locations) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 31, 2027 |
| Study ends | March 1, 2028 |
| Registry record updated | July 31, 2025 |
| Trial ID | NCT07097805 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People of any age with a clinical diagnosis of type 1 diabetes who are on insulin therapy or meet diagnostic criteria such as early onset, diabetic ketoacidosis at presentation, low C‑peptide, or positive islet autoantibodies are eligible.
✕Probably not a fit
Patients who already have excellent glycemic control with current care, those unable or unwilling to attend participating centers or engage in education/peer activities, and individuals with pancreas or islet transplants are unlikely to gain additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The GLITTER program implements a four-in-one management model that combines multidisciplinary clinical teams, structured education, peer support groups, and access to diabetes technologies. It is a multicenter, prospective cohort across several major hospitals in China and follows patients longitudinally to track metabolic control. Education is delivered through specialty clinics and local clinicians, while technology access (CGM and pumps) is offered but not mandated, and peer support is organized via patient communication groups. The aim is population-wide coverage and whole-disease-course management to increase the rate of patients reaching glycemic targets.
Why it matters
Potential benefit: If successful, this integrated approach could increase the proportion of people with type 1 diabetes who reach and maintain target blood glucose levels and reduce glycemic variability.
How similar studies have gone: Previous research shows that structured education, peer support, and diabetes technologies can each improve outcomes, but combining all four components in a single integrated program is less well tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Patients with type 1 diabetes of all age groups, regardless of disease duration. The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion. 1. Clinically diagnosed as Type 1 Diabetes by a specialist physician. 2. Meet any one of the following criteria: A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L 3. Meet any one of the following criteria: A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies
Where it's running
-
Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting -
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting -
Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting -
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China Recruiting -
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, China Recruiting -
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, Hunan, China Recruiting
Show 4 more locations
-
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China Recruiting -
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China Recruiting -
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University
Chengdu, Sichuan, China Recruiting -
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Xia Li
- Email: lixia2014@vip.163.com
- Phone: +86 13974885753
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Benefits of Retained Insulin for Good Health in Diabetes
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
-
Intermittent CGM Use in high-risk children and teens with Type 1 Diabetes in the Dominican Republic
This study tests whether using the Dexcom G7 intermittently, along with pediatric care and support, can improve glucose control in 10–19 year-olds with high-risk Type 1 Diabetes in the Dominican Republic.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
-
Dietary changes to help adults with Type 1 diabetes and overweight see if moderate carbs, time-restricted eating, or regular calories work
We’re testing three weight-loss approaches in adults with type 1 diabetes who are overweight or obese to see which helps reduce weight safely.
-
Islet re-transplantation after prior graft failure in adults with type 1 diabetes
This study looks at whether giving another islet transplant after a prior failed graft helps adults with type 1 diabetes who have severe swings in blood sugar.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.